Literature DB >> 16808809

The tetrapeptide acetyl-serine-aspartyl-lysine-proline improves skin flap survival and accelerates wound healing.

Yves Fromes1, Jian-Miao Liu, Milica Kovacevic, Jérôme Bignon, Joanna Wdzieczak-Bakala.   

Abstract

The tetrapeptide acetyl-serine-aspartyl-lysine-proline (AcSDKP) has recently been recognized as a potent angiogenic factor. Given the importance of vascular blood supply in the process of tissue repair we have investigated the ability of AcSDKP to contribute to the repair of cutaneous injuries by using dorsal and abdominal skin flap models. Postoperative subdermal AcSDKP injections (5 microg/kg/injection twice a day for 3 days following flap elevation) prevented marginally perfused areas from undergoing necrosis. Mean skin survival area of abdominal and dorsal flaps ranged, respectively, from 50.9+/-19.3 and 53.4+/-4.2% in the control groups to 66.4+/-7.5 and 74.7+/-6.6% in AcSDKP-treated groups. Furthermore, in an ex vivo assay, AcSDKP applied locally to skin explants at doses from 10(-8) to 10(-5) M improved survival of the explanted skin exposed to UVB irradiation at 10 J/cm2. Increased reepithelialization, as well as higher levels of expression of basal keratin 14 and increased expression of fibronectin was observed after topical application of AcSDKP. These data provide experimental evidence that AcSDKP can improve the viability of ischemic skin flaps in the rat by promoting angiogenesis. Moreover, it enhances wound healing of injured avascular skin explants. Thus, these findings identify AcSDKP as a new tissue-repair agent and suggest its potential clinical use for the management of skin wounds.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16808809     DOI: 10.1111/j.1743-6109.2006.00125.x

Source DB:  PubMed          Journal:  Wound Repair Regen        ISSN: 1067-1927            Impact factor:   3.617


  10 in total

1.  AcSDKP: a new potential marker of malignancy of the thyroid gland.

Authors:  Michal Kusinski; Joanna Wdzieczak-Bakala; Jian-Miao Liu; Jerome Bignon; Krzysztof Kuzdak
Journal:  Langenbecks Arch Surg       Date:  2006-01-18       Impact factor: 3.445

Review 2.  The biological significance of angiotensin-converting enzyme inhibition to combat kidney fibrosis.

Authors:  Takako Nagai; Kyoko Nitta; Megumi Kanasaki; Daisuke Koya; Keizo Kanasaki
Journal:  Clin Exp Nephrol       Date:  2014-07-01       Impact factor: 2.801

3.  A RHAMM mimetic peptide blocks hyaluronan signaling and reduces inflammation and fibrogenesis in excisional skin wounds.

Authors:  Cornelia Tolg; Sara R Hamilton; Ewa Zalinska; Lori McCulloch; Ripal Amin; Natalia Akentieva; Francoise Winnik; Rashmin Savani; Darius J Bagli; Len G Luyt; Mary K Cowman; Jim B McCarthy; Eva A Turley
Journal:  Am J Pathol       Date:  2012-08-11       Impact factor: 4.307

4.  Elevation of the antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline: a blood pressure-independent beneficial effect of angiotensin I-converting enzyme inhibitors.

Authors:  Megumi Kanasaki; Takako Nagai; Munehiro Kitada; Daisuke Koya; Keizo Kanasaki
Journal:  Fibrogenesis Tissue Repair       Date:  2011-11-30

Review 5.  N-acetyl-seryl-aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes.

Authors:  Keizo Kanasaki; Takako Nagai; Kyoko Nitta; Munehiro Kitada; Daisuke Koya
Journal:  Front Pharmacol       Date:  2014-04-14       Impact factor: 5.810

6.  N-acetyl-seryl-aspartyl-lysyl-proline inhibits diabetes-associated kidney fibrosis and endothelial-mesenchymal transition.

Authors:  Takako Nagai; Megumi Kanasaki; Swayam Prakash Srivastava; Yuka Nakamura; Yasuhito Ishigaki; Munehiro Kitada; Sen Shi; Keizo Kanasaki; Daisuke Koya
Journal:  Biomed Res Int       Date:  2014-03-24       Impact factor: 3.411

7.  Oral Administration of N-Acetyl-seryl-aspartyl-lysyl-proline Ameliorates Kidney Disease in Both Type 1 and Type 2 Diabetic Mice via a Therapeutic Regimen.

Authors:  Kyoko Nitta; Sen Shi; Takako Nagai; Megumi Kanasaki; Munehiro Kitada; Swayam Prakash Srivastava; Masakazu Haneda; Keizo Kanasaki; Daisuke Koya
Journal:  Biomed Res Int       Date:  2016-03-20       Impact factor: 3.411

Review 8.  N-acetyl-seryl-aspartyl-lysyl-proline is a valuable endogenous antifibrotic peptide for kidney fibrosis in diabetes: An update and translational aspects.

Authors:  Keizo Kanasaki
Journal:  J Diabetes Investig       Date:  2020-03-11       Impact factor: 4.232

9.  CD-1db/db mice: A novel type 2 diabetic mouse model with progressive kidney fibrosis.

Authors:  Yuiko Mizunuma; Keizo Kanasaki; Kyoko Nitta; Yuka Nakamura; Yasuhito Ishigaki; Yuta Takagaki; Munehiro Kitada; Shaolan Li; Haijie Liu; Jinpeng Li; Isao Usui; Yoshimasa Aso; Daisuke Koya
Journal:  J Diabetes Investig       Date:  2020-07-03       Impact factor: 4.232

10.  Effect of Antifibrotic MicroRNAs Crosstalk on the Action of N-acetyl-seryl-aspartyl-lysyl-proline in Diabetes-related Kidney Fibrosis.

Authors:  Swayam Prakash Srivastava; Sen Shi; Megumi Kanasaki; Takako Nagai; Munehiro Kitada; Jianhua He; Yuka Nakamura; Yasuhito Ishigaki; Keizo Kanasaki; Daisuke Koya
Journal:  Sci Rep       Date:  2016-07-18       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.